VL
VLG.LSE Venture Life Group PLC
- Market cap
- GBX 82.0M
- P/E
- -
- P/B
- 1.09x
- ROE
- 7.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is VLG.LSE undervalued?
Graham numberThe Graham number of Venture Life Group PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Venture Life Group PLC fundamental analysis
No fundamental analysis for Venture Life Group PLC yet.
Venture Life Group PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Venture Life Group PLC
Venture Life Group plc develops and commercializes healthcare products in the United Kingdom. The company offers women's healthcare products, including BV treatment gel and pessaries; intimate daily wash and soothing cream; moisture gel and plus pessaries; and thrush cream under Balance Activ name. It also provides glucose management products, such as Lift Glucose shots and tablets for the immediate treatment of hypoglycaemia and preventing hypos; and Glucogel for the treatm…
Full company profileVenture Life Group PLC financial statements
Venture Life Group PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 14.3M | 16.1M | 18.8M | 20.2M | 30.1M | 32.8M | 44.0M | 51.4M | 26.6M | 35.2M |
| Gross Profit | 5.49M | 6.47M | 7.29M | 8.00M | 12.8M | 13.0M | 17.7M | 20.2M | 12.2M | 11.8M |
| Operating Income | -465K | 581K | 1.05M | 1.28M | 3.56M | 1.37M | 2.23M | 3.29M | 1.52M | 1.05M |
| EBITDA | 573K | 1.77M | 2.60M | 2.80M | 5.60M | 5.16M | 7.61M | 9.95M | 4.32M | 5.08M |
| Net Income | -1.37M | -367K | 236K | 904K | 2.37M | 2.40M | 520K | 921K | -314K | 6.13M |
| EPS | -0.04 | -0.01 | 0.00 | 0.01 | 0.03 | 0.02 | 0.00 | 0.01 | 0.00 | 0.04 |
| Balance Sheet | ||||||||||
| Total Assets | 27.3M | 31.3M | 45.6M | 47.0M | 92.7M | 104M | 125M | 119M | 124M | 99.2M |
| Total Liabilities | 13.0M | 17.1M | 13.6M | 14.2M | 20.6M | 30.5M | 49.6M | 43.2M | 49.1M | 17.8M |
| Shareholders' Equity | 14.4M | 14.2M | 32.1M | 32.8M | 72.1M | 73.2M | 75.7M | 76.3M | 75.4M | 81.4M |
| Cash & Short-term Investments | 2.00M | 1.36M | 9.62M | 5.16M | 42.1M | 5.24M | 5.63M | 5.62M | 3.05M | 34.2M |
| Total Debt | 7.14M | 11.4M | 7.07M | 7.03M | 11.2M | 12.7M | 26.8M | 24.4M | 23.9M | 667K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -457K | -84.0K | 238K | 2.44M | 2.71M | 601K | 5.57M | 8.22M | 8.35M | -264K |
| Capital Expenditure | 540K | 853K | 1.02M | 1.15M | 2.07M | 3.26M | 4.21M | 2.41M | 10.0K | 45.0K |
| Free Cash Flow | -997K | -937K | -777K | 1.30M | 637K | -2.66M | 1.36M | 5.81M | 8.34M | -309K |
| Ratios | ||||||||||
| ROE | -9.5% | -2.6% | 0.7% | 2.8% | 3.3% | 3.3% | 0.7% | 1.2% | -0.4% | 7.5% |
| ROA | -5.0% | -1.2% | 0.5% | 1.9% | 2.6% | 2.3% | 0.4% | 0.8% | -0.3% | 6.2% |
| Net Profit Margin | -9.6% | -2.3% | 1.3% | 4.5% | 7.9% | 7.3% | 1.2% | 1.8% | -1.2% | 17.4% |
| Debt to Equity | 0.50x | 0.80x | 0.22x | 0.21x | 0.16x | 0.17x | 0.35x | 0.32x | 0.32x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Venture Life Group PLC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 24, 2018
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | GBP 14.0K | 0.00 | 5.9% |
| 2017 | GBP 15.0K | 0.00 | - |
| 2016 | GBP 14.0K | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 722:721 on Nov 23, 2020.
Who owns Venture Life Group PLC
- Insiders 10.26%
- Institutions 69.24%
- Public & others 20.50%
- Shares outstanding 119M
- Free float 105M
Venture Life Group PLC company profile
- Company name
- Venture Life Group PLC
- Ticker
- VLG.LSE
- ISIN
- GB00BFPM8908
- Exchange
- London Exchange
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Employees
- 63
- Fiscal year end
- December
- Address
- 12 The Courtyard, Bracknell, United Kingdom, RG12 2XB
- Phone
- 44 13 4457 8004
- Website
- venture-life.com
About Venture Life Group PLC
Venture Life Group plc develops and commercializes healthcare products in the United Kingdom. The company offers women's healthcare products, including BV treatment gel and pessaries; intimate daily wash and soothing cream; moisture gel and plus pessaries; and thrush cream under Balance Activ name. It also provides glucose management products, such as Lift Glucose shots and tablets for the immediate treatment of hypoglycaemia and preventing hypos; and Glucogel for the treatment of hypoglycaemia. In addition, the company offers ENT care products comprising Earol, for the removal of ear wax; EarolSwim, an invisible ear plugs for protecting the ears from water ingress; and Baby Earol, an ear spray for babies under the Earol and EarolSwim brands. Further, it provides oncology support products, such as Pomi-T for the management of prostate-specific antigen levels in prostate cancer; and Gelclair, a muco-adhesive oral rinse for the treatment of Oral Mucositis. The company operates in Germany, the Netherlands, Norway, France, Sweden, Denmark, Lithuania, rest of Europe, the United States, Canada, Brazil, Ireland, and internationally. Venture Life Group plc was incorporated in 2005 and is headquartered in Bracknell, the United Kingdom.
Venture Life Group PLC management
9- Mr. Jeremy Anthony Philip Randall ACACo-Founder, CEO & Executive Director · born 1964
- Mr. Daniel James WellsCFO & Director · born 1987
- Mr. Peter Robert JacksonChief Digital and Technology Officer & Director · born 1968
- Ms. Katherine Louise BacheChief Marketing & Innovation Officer and Director · born 1981
- Ben ColmanDirector of Corporate Development
- Mr. Domenico BarbaroHead of Procurement
- Mr. Ennio SchiroHead of ESG Strategy
- Mr. Matt JeffsHead of M&A
- Louise McCarthyCompany Secretary